Vadastuximab

Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine[1].

Product Specifications

CAS Number

[1436390-63-4]

Product Name Alternative

Anti-Human CD33 Recombinant Antibody

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vadastuximab.html

Purity

99.23

Solubility

10 mM in DMSO

Smiles

[Vadastuximab]

Molecular Weight

(144.78 kDa)

References & Citations

[1]Eytan M Stein, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018 Jan 25;131 (4) :387-396.